Results 91 to 100 of about 2,690,705 (301)
Biomedical research relies on proving (or disproving) a research hypothesis, and P value becomes a cornerstone of “null hypothesis significance testing.” P value is the maximum probability of getting the observed outcome by chance. For a statistical test
Amrita Sil +2 more
doaj +1 more source
PICALM::MLLT10 translocated leukemia
This comprehensive review of PICALM::MLLT10 translocated acute leukemia provides an in‐depth review of the structure and function of CALM, AF10, and the fusion oncoprotein (1). The multifaceted molecular mechanisms of oncogenesis, including nucleocytoplasmic shuttling (2), epigenetic modifications (3), and disruption of endocytosis (4), are then ...
John M. Cullen +7 more
wiley +1 more source
Testing the Conditional Convergence Hypothesis for Pakistan [PDF]
This study investigates for the existence or non-existence of conditional convergence across the provinces of Pakistan. The annual output data from 1973 to 2000 is pooled for the four Pakistani provinces.
Sajjad Ahmad Jan (Corresponding Author) +1 more
doaj
Water loss in tree weta (Hemideina): adaptation to the montane environment and a test of the melanisation–desiccation resistance hypothesis [PDF]
Keith King, Brent J. Sinclair
openalex +1 more source
At low cell density, SETDB1 and YAP1 accumulate in the nucleus. As cell density increases, the Hippo pathway is gradually activated, and SETDB1 is associated with increased YAP1 phosphorylation. At high cell density, phosphorylated YAP1 is sequestered in the cytoplasm, while SETDB1 becomes polyubiquitinated and degraded by the ubiquitin–proteasome ...
Jaemin Eom +3 more
wiley +1 more source
Binary discrimination in two-level quantum systems via hypothesis testing [PDF]
Beili Gong, Wei Cui
openalex +1 more source
β‐TrCP overexpression enhances cisplatin sensitivity by depleting BRCA1
Low levels of β‐TrCP (Panel A) allow the accumulation of BRCA1 and CtIP, which facilitate the repair of cisplatin‐induced DNA damage via homologous recombination (HR) and promote tumor cell survival. In contrast, high β‐TrCP expression (Panel B) leads to BRCA1 and CtIP degradation, impairing HR repair, resulting in persistent DNA damage and apoptosis ...
Rocío Jiménez‐Guerrero +8 more
wiley +1 more source
PARP inhibitors are used to treat a small subset of prostate cancer patients. These studies reveal that PARP1 activity and expression are different between European American and African American prostate cancer tissue samples. Additionally, different PARP inhibitors cause unique and overlapping transcriptional changes, notably, p53 pathway upregulation.
Moriah L. Cunningham +21 more
wiley +1 more source
Finite Sample Hypothesis Tests for Stacked Estimating Equations [PDF]
Eli S. Kravitz +2 more
openalex +1 more source

